ReviewFrontiers in medicine2022
HTLV-1 and Co-infections.
Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- HTLV-1-associated diseases: a systematic review.Revista do Instituto de Medicina Tropical de Sao Paulo · 2026Pooled it
- Advances in preventive vaccine development against HTLV-1 infection: A systematic review of the last 35 years.Frontiers in immunology · 2023Pooled it
- The Prevalence of Syphilis, HTLV I/II, and Malaria Among Blood Donors at the Riyadh Regional Laboratory: A Retrospective Study from Saudi Arabia.Journal of clinical medicine · 2026Article
- Experiences from Two Decades of HTLV-1/2 Testing in a Low-Prevalence Area in Southern Germany, 2004 to 2024.Viruses · 2026Article
- Bovine Leukemia Virus as a One Health Challenge in Nutrition, Food Security, and Public Health: A Narrative Review.The Journal of nutrition · 2026Review
- Prevalence of HTLV-1 and HTLV-2 infection among transgender women in Brazil: A multicenter study.PLoS neglected tropical diseases · 2026Article
- Primary causes of hospital admission in HTLV-1 infected patients: infectious complications, predictors of mortality and long-term survival outcomes.BMC infectious diseases · 2026Article
- Morbidity and Mortality Among People Living With HTLV-1: A 30-Year Retrospective Analysis in a Brazilian Cohort.Journal of medical virology · 2026Article
- Epidemiology and Clinical Outcomes of HTLV-1: A Comprehensive Narrative Review of Endemic and Nonendemic Regions.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Review
- Seroprevalence Assessment of HTLV-1 and Its Related Risk Factors in Patients With Rheumatoid Arthritis in Gonabad in 2023.Clinical medicine insights. Arthritis and musculoskeletal disorders · 2026Article
- FC-duplex IgG1 (HTLV-1/2): Qualifying the flow cytometry IgG1 duplex assay for differential diagnosis of HTLV-1 and HTLV-2 infections.PLoS neglected tropical diseases · 2025Article
- HTLV-1 in Pregnancy and Neonatal Health: Evidence, Challenges, and Future Directions.Diagnostics (Basel, Switzerland) · 2025Review
- Epidemiological, clinical and immunological features of Schistosoma spp., Stronglyoides stercoralis and Taenia spp. infections in Ghanaian HIV patients.European journal of microbiology & immunology · 2025Article
- Tricky with Heat and Salt: Soil Factors, Thermotaxis, and Potential for Heat-Saline Agar Trapping ofBiology · 2025Article
- T-Cell Receptor/CD3 Downregulation and Impaired Signaling in HTLV-1-Infected CD4+ T Cells of HAM Patients.International journal of molecular sciences · 2025Article
- A case of lower respiratory tract infection caused byIDCases · 2025Article
- Experience in the management of patients with HTLV-1 positive adult T-cell leukemia/lymphoma in a Latin American center.Therapeutic advances in hematology · 2025Article
- Review
- Neurological aspects of HTLV-1 infection: symptoms in apparently asymptomatic carriers.Journal of neurovirology · 2024Observational
- Human T-Lymphotropic Virus Type 1 and Cryptococcosis Infection, an Underdiagnosed Association: Case Series and Literature Review.Open forum infectious diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human T lymphotropic virus type 1 (HTLV-1) is a retrovirus that causes lifelong T-cell infection in humans, impacting the host immune response. This virus causes a range of clinical manifestations, from inflammatory conditions, including neuronal damage (HTLV-1 associated myelopathy, HAM) to life-threatening leukemia (adult T-cell leukemia, ATL). Human T lymphotropic virus type 1 is also associated with increased risk of all-cause mortality, but the mechanisms remain unclear. As a blood-borne and sexually transmitted infection (STI), HTLV-1 shares transmission routes to many other pathogens and although it has worldwide distribution, it affects mainly those in low- and middle-income tropical areas, where the prevalence of other infectious agents is high. These factors contribute to a high incidence of co-infections in people living with HTLV-1 (PLHTLV). This comprehensive review addresses the impact of HTLV-1 on several co-infections and vice-versa. There is evidence of higher rates of HTLV-1 infection in association with other blood borne (HCV, HBV) and sexually transmitted (Syphilis, Chlamydia, HPV, HSV) infections but whether this represents increased susceptibility or opportunity is unclear. Higher frequency of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.